The severe acute respiratory syndrome coronavirus 2 variant JN.1 recently emerged as the dominant variant despite having only one amino acid change on the spike (S) protein receptor binding domain (RBD) compared with the ancestral BA.2.86, which never represented more than 5% of global variants. To define at the molecular level the JN.1 ability to spread globally, we interrogated a panel of 899 neutralizing human monoclonal antibodies. Our data show that the single leucine-455-to-serine mutation in the JN.1 spike protein RBD unleashed the global spread of JN.1, likely occurring by elimination of more than 70% of the neutralizing antibodies mediated by IGHV3-53/3-66 germlines. However, the resilience of class 3 antibodies with low neutralization potency but strong Fc functions may explain the absence of JN.1 severe disease.

Paciello, I., Maccari, G., Pierleoni, G., Perrone, F., Realini, G., Troisi, M., et al. (2024). SARS-CoV-2 JN.1 variant evasion of IGHV3-53/3-66 B cell germlines. SCIENCE IMMUNOLOGY, 9(98) [10.1126/sciimmunol.adp9279].

SARS-CoV-2 JN.1 variant evasion of IGHV3-53/3-66 B cell germlines

Pierleoni, Giulio;Perrone, Federica;Realini, Giulia;Troisi, Marco;Anichini, Gabriele;Cusi, Maria Grazia;Rappuoli, Rino;Andreano, Emanuele
2024-01-01

Abstract

The severe acute respiratory syndrome coronavirus 2 variant JN.1 recently emerged as the dominant variant despite having only one amino acid change on the spike (S) protein receptor binding domain (RBD) compared with the ancestral BA.2.86, which never represented more than 5% of global variants. To define at the molecular level the JN.1 ability to spread globally, we interrogated a panel of 899 neutralizing human monoclonal antibodies. Our data show that the single leucine-455-to-serine mutation in the JN.1 spike protein RBD unleashed the global spread of JN.1, likely occurring by elimination of more than 70% of the neutralizing antibodies mediated by IGHV3-53/3-66 germlines. However, the resilience of class 3 antibodies with low neutralization potency but strong Fc functions may explain the absence of JN.1 severe disease.
2024
Paciello, I., Maccari, G., Pierleoni, G., Perrone, F., Realini, G., Troisi, M., et al. (2024). SARS-CoV-2 JN.1 variant evasion of IGHV3-53/3-66 B cell germlines. SCIENCE IMMUNOLOGY, 9(98) [10.1126/sciimmunol.adp9279].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1272554